Our Pipeline:

The company’s product candidate, VDPHL, has the potential to become the first oral treatment approved for the treatment of pattern hair loss (PHL) for both men and women.  Pattern hair loss affects 80 million Americans, more than 12 million of whom seek treatment for their hair loss. Resultantly, PHL is a multi-billion-dollar global market that has a stagnant treatment landscape with no novel approvals in more than 20 years. Existing approved treatments include topical minoxidil which is discontinued by nearly 90% of individuals who begin using it and oral finasteride which is only approved for use for men with PHL, and which is associated with the development of sexual side effects including erectile dysfunction.